Compare KORE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | LUNG |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 63.6M |
| IPO Year | N/A | 2020 |
| Metric | KORE | LUNG |
|---|---|---|
| Price | $4.60 | $2.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $6.81 |
| AVG Volume (30 Days) | 57.0K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,408,000.00 | $91,664,000.00 |
| Revenue This Year | $1.26 | $9.21 |
| Revenue Next Year | $7.55 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.06 | ★ 15.59 |
| 52 Week Low | $1.10 | $1.31 |
| 52 Week High | $4.88 | $9.37 |
| Indicator | KORE | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 65.14 | 68.25 |
| Support Level | $4.25 | $1.96 |
| Resistance Level | $4.61 | $2.66 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 98.44 | 84.40 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.